20S Proteasome Videos

Videos

Dr Laubach Reviews Phase 2 GRIFFIN Study Results in Newly Diagnosed MM

01/10/2022

Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.

Jacob Laubach, MD, MPP,...

01/10/2022

Oncology

Videos

Dr Mithraprabhu Discusses Liquid Biopsy to Define Genomic Characteristics of Patients With MM

12/02/2021

Dr Sridurga Mithraprabhu, discusses liquid biopsy, which can be utilized to define the genomic characteristics of a patient with MM.

Dr Sridurga Mithraprabhu,...

12/02/2021

Oncology

Videos

Daratumumab-Based Triplet Therapy More Effective Than Doublet for MM

09/15/2021

Meletios Dimopoulos, MD, discusses the phase 3 APOLLO study on adding daratumumab to pomalidomide and low-dose dexamethasone for patients with MM.

Meletios Dimopoulos, MD,...

09/15/2021

Oncology

Videos

Dr Jain Discusses High-Risk MCL: Definition, Current Challenges, and Management

02/09/2021

Preetesh Jain, MBBS, MD, DM, PhD, discusses a study that explores the definition, current challenges, and management of high-risk MCL.

Preetesh Jain, MBBS, MD, DM,...

02/09/2021

Oncology

Videos

Dr Tam Discusses Ibrutinib Therapy Plus Venetoclax for R/R MCL

12/07/2020

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study", presented...

Constantine Tam, MBBS (Hons),...

12/07/2020

Oncology

$Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM$

Videos

Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM

12/05/2020

In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.

In this video, Dr Chari...

12/05/2020

Oncology

$Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL$

Videos

Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL

04/24/2020

Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.

Mehdi Hamadani, MD, weighs the...

04/24/2020

Oncology

Videos

Immunotherapies in Multiple Myeloma

10/25/2019

David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.

David E. Avigan, MD discusses...

10/25/2019

Oncology

Videos

Key Insights in Multiple Myeloma

02/27/2018

Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016.

Drs Morton Coleman and Ruben...

02/27/2018

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology